<code id='B14817DF45'></code><style id='B14817DF45'></style>
    • <acronym id='B14817DF45'></acronym>
      <center id='B14817DF45'><center id='B14817DF45'><tfoot id='B14817DF45'></tfoot></center><abbr id='B14817DF45'><dir id='B14817DF45'><tfoot id='B14817DF45'></tfoot><noframes id='B14817DF45'>

    • <optgroup id='B14817DF45'><strike id='B14817DF45'><sup id='B14817DF45'></sup></strike><code id='B14817DF45'></code></optgroup>
        1. <b id='B14817DF45'><label id='B14817DF45'><select id='B14817DF45'><dt id='B14817DF45'><span id='B14817DF45'></span></dt></select></label></b><u id='B14817DF45'></u>
          <i id='B14817DF45'><strike id='B14817DF45'><tt id='B14817DF45'><pre id='B14817DF45'></pre></tt></strike></i>

          Home / entertainment / knowledge

          knowledge


          knowledge

          author:leisure time    Page View:95

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In